Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. (April 2022)
- Record Type:
- Journal Article
- Title:
- Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. (April 2022)
- Main Title:
- Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum
- Authors:
- Rosebraugh, Matthew
Stodtmann, Sven
Liu, Wei
Facheris, Maurizio F. - Abstract:
- Abstract: Introduction: The objective of this study was to compare the pharmacokinetics (PK) of levodopa (LD) from 24-h continuous subcutaneous infusion of foslevodopa/foscarbidopa to the LD pharmacokinetics from 16-h levodopa-carbidopa intestinal gel (LCIG) followed by night-time oral LD/carbidopa (CD) doses. Methods: This was a Phase 1, open-label, randomized, 2-period crossover study conducted in 25 male and female healthy volunteers. Results: The LD exposures (Cmax0-16, AUC0-16 and AUC∞) following subcutaneous infusion of 700/35 mg foslevodopa/foscarbidopa over 24 h were similar (<8% difference) to those of LCIG 350/87.5 mg LD/CD administered over 16 h followed by two 100/25 mg LD/CD oral doses at 18 and 21 h after the start of LCIG delivery. Conclusion: Foslevodopa/foscarbidopa subcutaneous infusion provides levodopa exposures comparable to LCIG throughout the day. ClinicalTrials.gov identifier: Not Applicable. Highlights: Foslevodopa/foscarbidopa LD exposures are comparable to LCIG in healthy volunteers. LD degree of fluctuation was low for foslevodopa/foscarbidopa infusion and LCIG. Foslevodopa/foscarbidopa maintains LD exposure within a narrow therapeutic window.
- Is Part Of:
- Parkinsonism & related disorders. Volume 97(2022)
- Journal:
- Parkinsonism & related disorders
- Issue:
- Volume 97(2022)
- Issue Display:
- Volume 97, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 97
- Issue:
- 2022
- Issue Sort Value:
- 2022-0097-2022-0000
- Page Start:
- 68
- Page End:
- 72
- Publication Date:
- 2022-04
- Subjects:
- Levodopa -- Carbidopa -- Parkinson's disease -- Pharmacokinetics
Parkinson's disease -- Periodicals
Movement disorders -- Periodicals
Movement Disorders -- Periodicals
Nerve Degeneration -- Periodicals
Nervous System Diseases -- Periodicals
Parkinson Disease -- Periodicals
Tremor -- Periodicals
Parkinson, Maladie de -- Périodiques
Parkinson's disease
616.833 - Journal URLs:
- http://www.sciencedirect.com/science/journal/13538020 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/13538020 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/13538020 ↗
http://www.prd-journal.com/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.parkreldis.2022.03.012 ↗
- Languages:
- English
- ISSNs:
- 1353-8020
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6406.787000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21568.xml